Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Vertex Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Accounts payable
Accrued expenses
Other current liabilities
Current liabilities
Long-term operating lease liabilities
Other long-term liabilities
Long-term liabilities
Total liabilities
Preferred stock, $0.01 par value; none issued
Common stock, $0.01 par value
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings (accumulated deficit)
Shareholders’ equity
Total liabilities and shareholders’ equity

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Accounts Payable
The proportion of accounts payable relative to total liabilities and shareholders’ equity shows minor fluctuations within the range of approximately 0.95% to 1.94%. The metric exhibits a slight upward trend towards the end of the period, peaking near 1.94% in the third quarter of 2025 before decreasing slightly to 1.69% in the last reported quarter.
Accrued Expenses
Accrued expenses generally vary between 11.68% and 15.13%. The data reveals some volatility across quarters, with an overall tendency to remain around the mid-teens percentage. Notably, there is a decrease around the first quarter of 2021 and late 2023, followed by recoveries in subsequent periods.
Other Current Liabilities
This category generally fluctuates between around 1.3% and 2.7%. It experiences moderate volatility but no strong directional trend, with peaks in late 2020 and early 2024.
Current Liabilities
Current liabilities as a percentage of total liabilities and shareholders’ equity remain relatively stable, mostly ranging from about 15% to 18%. Although there are some dips and rises, the trend does not display significant long-term increase or decrease, suggesting steady management of short-term obligations.
Long-term Operating Lease Liabilities
This liability emerges in the data starting in December 2020, initially around 2.98%, and then declines gradually until mid-2024 when it surges sharply, peaking at 7.38% by the last quarter of 2025. This indicates a substantial increase in lease obligations in recent periods.
Other Long-term Liabilities
Other long-term liabilities show a declining trend from over 10% early in 2020 to approximately 4.96% by the end of 2025. This steady decrease could indicate the repayment or restructuring of some long-term obligations.
Long-term Liabilities
Long-term liabilities also decrease from above 10% in 2020 to a low near 6.58% in mid-2024 before rising again later. The latter increase corresponds with the increase observed in long-term operating leases, reflecting a changing composition in long-term obligations.
Total Liabilities
Total liabilities remain generally stable between approximately 22% and 30%, with some upward volatility toward late 2024 and early 2025. This suggests fluctuating but controlled overall indebtedness relative to total capital.
Common Stock
The share of common stock relative to total liabilities and shareholders’ equity remains negligible and almost constant over time, close to 0.01% to 0.03%.
Additional Paid-in Capital
There is a notable continuous downward trend in additional paid-in capital as a percentage of total liabilities and shareholders’ equity, starting from above 86% in early 2020 and decreasing steadily to around 20.16% by late 2025. This could reflect share repurchases, amortization of premiums, or other capital structure changes.
Accumulated Other Comprehensive Income (Loss)
This item fluctuates narrowly around zero, with occasional positive and negative values, indicating limited and volatile comprehensive income impacts on equity.
Retained Earnings (Accumulated Deficit)
Retained earnings as a proportion of total liabilities and shareholders’ equity show a strong upward trend, increasing from a negative position early in 2020 (-14%) to nearly 50% by late 2025. This significant positive shift suggests accumulated profitability and reinvestment of earnings over the period.
Shareholders’ Equity
Shareholders’ equity generally remains around 70% to 77%, displaying relative stability despite fluctuations in other components such as additional paid-in capital and retained earnings. There is a mild declining trend towards the last quarters.
Total Liabilities and Shareholders’ Equity
As expected, this remains constant at 100%, reflecting the balance sheet equation.